Equities Analysts Set Expectations for Medpace Holdings Inc’s FY2017 Earnings (MEDP)
Medpace Holdings Inc (NASDAQ:MEDP) – Investment analysts at KeyCorp upped their FY2017 earnings per share estimates for shares of Medpace Holdings in a research report issued to clients and investors on Monday. KeyCorp analyst D. Hooker now expects that the company will post earnings of $1.49 per share for the year, up from their prior forecast of $1.37. KeyCorp currently has a “Hold” rating on the stock. KeyCorp also issued estimates for Medpace Holdings’ Q4 2017 earnings at $0.37 EPS and FY2018 earnings at $1.72 EPS.
Medpace Holdings (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.04. Medpace Holdings had a net margin of 8.89% and a return on equity of 6.80%. The business had revenue of $98.68 million during the quarter, compared to the consensus estimate of $96.84 million. During the same period in the prior year, the firm posted $0.40 EPS. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year.
Several other brokerages have also recently issued reports on MEDP. William Blair cut shares of Medpace Holdings from an “outperform” rating to a “market perform” rating in a report on Wednesday. They noted that the move was a valuation call. Jefferies Group LLC boosted their target price on shares of Medpace Holdings from $34.00 to $38.00 and gave the company a “hold” rating in a research report on Wednesday. Robert W. Baird boosted their target price on shares of Medpace Holdings from $32.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday. Zacks Investment Research lowered shares of Medpace Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, Raymond James Financial, Inc. initiated coverage on shares of Medpace Holdings in a research report on Friday, September 29th. They set a “market perform” rating for the company. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Medpace Holdings has a consensus rating of “Hold” and a consensus price target of $36.20.
In other Medpace Holdings news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $30.27, for a total transaction of $60,540,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 25.80% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. First Quadrant L P CA purchased a new position in shares of Medpace Holdings in the 3rd quarter valued at approximately $119,000. American International Group Inc. purchased a new position in shares of Medpace Holdings in the 1st quarter valued at approximately $145,000. Tudor Investment Corp ET AL raised its position in shares of Medpace Holdings by 16.4% in the 1st quarter. Tudor Investment Corp ET AL now owns 6,864 shares of the company’s stock valued at $205,000 after purchasing an additional 967 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Medpace Holdings in the 2nd quarter valued at approximately $220,000. Finally, Credit Suisse AG purchased a new position in shares of Medpace Holdings in the 1st quarter valued at approximately $231,000. 16.32% of the stock is owned by hedge funds and other institutional investors.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.